Document is current

Article History

Received: 18 March 2025

Accepted: 21 July 2025

First Online: 22 August 2025

Declarations

:

: KAS, DB, SJ, PT, DV, JM-B, LMO, RH, CM, and NHP declare no competing interests. JK reports funding from the National Institute of Neurological Disorders and Stroke and the Brain Aneurysm Foundation. AdH has received consultant fees from Integra and Novo Nordisk and royalty fees from UpToDate and has equity in TitinKM and Certus. KNS reports compensation from Bexorg for consultant services; employment by Yale School of Medicine; compensation from Sense for data and safety monitoring services; compensation from Philips for data and safety monitoring services; compensation from Astrocyte for consultant services; stock holdings in AbbVie; compensation from Rhaeos for consultant services; stock options in BrainQ; a patent pending for Stroke wearables licensed to Alva Health; and grants from Hyperfine and Genentech. EJG reports funding from the National Institutes of Health (R01 NS117904). SO-G reports grants from the National Institutes of Health National Institute of Neurological Disorders and Stroke (RO1NS127114-01, RO1NS138765, RO3NS126804), PCORI, Stryker, Medtronic, and Methinks; consulting fees from Medtronic and Stryker Neurovascular; serving as overall principal investigator (PI) for US tandem Registry, DIRECT, DONE SYMPLE, and MAPSTROKE; serving as co-PI for VOTER registry, ATHENA, and SMART-LVO; serving as institutional PI and on the steering committee for SEGA, TESLA, ENDOLOW and SELECT 2, SPLENDID, SUMMIT, and MYSTIQUE; and stocks/shares in Brainflow, Gravity, and Motif.

: Ethical approval for this study was obtained from the institutional review board. Given the retrospective nature of the study and the minimal risk to participants, the requirement for individual informed consent was waived. This research was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.